Tari Leslie's Form 4 filing
Cidara Therapeutics, Inc. (CDTX) · filed Jan 27, 2023
- Accession no.
- 0001610618-23-000003
- Filed
- Jan 27, 2023
- Trade date
- Jan 12, 2023
- Filing delay
- 15 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $14.2K. It was filed 15 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tari LeslieCIK 0001870270 | Officer (CHIEF SCIENTIFIC OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2023 | Common Stock | SSaleDisposed | −11,814 | $1.20 | −$14,176.8 | 1,484 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.